1-3 of 3
Stephane Doucet, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Gemcitabine, Dexamethasone, Cisplatin +/- Rituximab (GDP +/- R) Is Highly Effective As a Mobilization Regimen in Relapsed or Refractory Lymphoma (COLLYM STUDY)

Jean-Philippe Adam, BPharm, MSc, Vincent T. Taillefer, Pharm.D, Marianne Emond, B.Pharm, M.Sc, BCOP, Marie-Hélène Leblanc, B.Pharm, M.Sc, BCOP, Olivier Besner-Morin, B.Pharm, M.Sc, Stephane Doucet, MD FRCPC
Journal: Blood
Blood (2018) 132 (Supplement 1): 3348.
https://doi.org/10.1182/blood-2018-99-115539
Published: 2018
Journal Articles

Rituximab Maintenance for Two Years in Previously Untreated Follicular Lymphoma: No Difference in Outcome between Patients Receiving Treatment at Two Month Versus Three Month Interval

Claudie Roy, MD, Isabelle Fleury, MD MSc, FRCPC, Jao Kevin, MD FRCP, Stephane Doucet, MD FRCP
Journal: Blood
Blood (2017) 130 (Supplement 1): 4064.
https://doi.org/10.1182/blood.V130.Suppl_1.4064.4064
Published: 2017
Journal Articles

D-DImer Dosing for Risk Prediction of Central Venous Catheter Thrombosis (The DIReCT Trial).

Stephane Doucet, MD, Marie-Jose Miron, MD, Soulieres Denis, MD, Belanger Karl, MD, Florescu Marie, MD, Ayoub Jean-Pierre, MD, Yelle Louise, MD, Harold J. Olney, MD, Normand Blais, MD
Journal: Blood
Blood (2007) 110 (11): 3980.
https://doi.org/10.1182/blood.V110.11.3980.3980
Published: 2007